JWH-193

JWH-193

Systematic (IUPAC) name
(1-(2-morpholin-4-ylethyl)indol-3-yl)-4-methylnaphthalen-1-ylmethanone
Clinical data
Legal status	CA: Schedule II
Identifiers
CAS Number	133438-58-1 Y
PubChem	CID: 10250276
ChemSpider	8425762
UNII	WB1TIJ1IO9 Y
Chemical data
Formula	C26H26N2O2
Molecular mass	398.496 g/mol
SMILES c3cccc1c3c(ccc1C)C(=O)c5c2ccccc2n(c5)CCN4CCOCC4
InChI InChI=1S/C26H26N2O2/c1-19-10-11-23(21-7-3-2-6-20(19)21)26(29)24-18-28(25-9-5-4-8-22(24)25)13-12-27-14-16-30-17-15-27/h2-11,18H,12-17H2,1H3 Key:ICKWPPYMDARCKJ-UHFFFAOYSA-N
(verify)

JWH-193 is a drug from the aminoalkylindole family which acts as a cannabinoid receptor agonist. It was invented by the pharmaceutical company Sanofi-Winthrop in the early 1990s. JWH-193 has a binding affinity at the CB₁ receptor of 6nM, binding around seven times more tightly than the parent compound JWH-200, though with closer to twice the potency of JWH-200 in activity tests. A structural isomer of JWH-193 with the methyl group on the indole ring instead of the naphthoyl ring, was also found to be of similarly increased potency over JWH-200.

6-Methyl-JWH-200

See also

• JWH-122
• JWH-198